Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE EBITDA Margin

EBITDA as a percentage of revenue.

Maze Therapeutics, Inc.NASDAQ: MAZE

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin at -114.5%

EBITDA Margin was -114.5% in Q1 FY2026. On a trailing-twelve-month basis it was -597.6%, down 631.1 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-114.5%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
-597.6%-631.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2024
33.9%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How MAZE compares with its peers on the latest reported figures

  • MAZE's LTM Mar 2026 EBITDA Margin of -597.6% is the 5th highest of the 7 companies compared; the peer median is -37.8%.
  • Its year-over-year change of -631.1 pp is the 6th highest of 7, against a peer median of -4.7 pp.
MAZE Competitors Peer median
EBITDA Margin for MAZE and competitors
Company Period LTM level YoY 3-year change
PTCTPTC Therapeutics, Inc.LTM Jun 202617.2% -30.5 pp+103.9 pp
ARDXArdelyx, Inc.LTM Mar 2026-6.0% +1.8 pp+109.8 pp
TVTXTravere Therapeutics, Inc.LTM Sep 2026-16.4% -11.2 pp+278.1 pp
SEPNSepterna, Inc.LTM Sep 2026-59.3% +282.9 pp—
MAZEMaze Therapeutics, Inc.LTM Mar 2026-597.6% -631.1 pp—
BIOABioAge Labs, Inc.LTM Mar 2026-864.8% +3922.9 pp—
IVAInventiva S.A.FY2025-2858.6% -1048.1 pp-2396.4 pp
DMACDiaMedica Therapeutics Inc.FY2025— ——
Peer median (excluding MAZE) -37.8%-4.7 pp+106.8 pp

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.